Sedatives

Procymate (Equipax) is a carbamate derivative which is a sedative and anxiolytic drug. It was previously manufactured and marketed in Belgium. The usual dose for adults is 800 to 1200 mg per day. Procymate shares a similar structure and mechanism of action with the related drugs hexapropymate and phenprobamate.

Anhalonidine, also known as '''N-desmethylpellotine', a naturally occurring tetrahydroisoquinoline alkaloid which can be isolated from certain members of the cactus family, such as Lophophora''. It is structurally related to mescaline. Anhalonidine produced no hallucinogenic effects in humans at doses of up to 250mg. However, it has been reported to have a calming or sedative effect instead, with about one-fourth the potency of pellotine and with marked sedation occurring at doses of 100 to 250mg. Anhalonidine has been found to act as a potent inverse agonist of the serotonin 5-HT7 receptor.

JM-1232 is a sedative and hypnotic drug being researched as a potential anesthetic. It has similar effects to sedative-hypnotic benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic. It was developed by a team at Maruishi Pharmaceutica.

Saripidem is a sedative and anxiolytic drug in the imidazopyridine family, which is related to the better known drugs zolpidem and alpidem.

Diproqualone is a quinazolinone class GABAergic and is an analogue of methaqualone developed in the late 1950s by a team at Nogentaise de Produits Chimique. It was marketed primarily in France and some other European countries. It has sedative, anxiolytic, antihistamine and analgesic properties, resulting from its agonist activity at the β subtype of the GABAa receptor, antagonist activity at all histamine receptors, inhibition of the cyclooxygenase-1 enzyme, and possibly its agonist activity at both the sigma-1 receptor and sigma-2 receptor (the function of these receptors and their clinical

Pipequaline (INN; development code PK-8165) is an anxiolytic drug that was never marketed. It possesses a novel chemical structure that is not closely related to other drugs of this type. The drug has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and very little sedative, amnestic or anticonvulsant effects, and so is classified as a nonbenzodiazepine anxiolytic.

Suriclone (Suril) is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs. Other cyclopyrrolone drugs include zopiclone and pagoclone.

Metomidate is a non-barbiturate imidazole that was discovered by Janssen Pharmaceutica in 1965 and under the names (Hypnodil, Nokemyl) is sold as a sedative-hypnotic drug used in Europe to treat humans and for veterinary purposes.

Taniplon is a nonbenzodiazepine anxiolytic drug from the imidazoquinazoline family of drugs.

Nisobamate (INN; W-1015) is a tranquilizer of the carbamate family which was never marketed.

Pazinaclone (DN-2327) is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs. Some other cyclopyrrolone drugs include zopiclone and eszopiclone.

γ-Hydroxybutyraldehyde is the organic compound with the formula HOCH2CH2CH2CHO. It is a colorless liquid. The compound occurs in nature and is produced commercially.

Petrichloral (pentaerythritol chloral, brand name Periclor) is a sedative and hypnotic chloral hydrate prodrug. It is a Schedule IV drug in the USA.

effect of alcohol consumption

Metaglycodol (INN) is a drug described as a tranquilizer which was never marketed.

Clocental (dolcental) is a carbamate-derived sedative hypnotic.

Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type. It has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and relatively little sedative or amnestic effect, and so is classified as a nonbenzodiazepine anxiolytic.

Dimdazenil, sold under the brand name Junoenil, is a medication used in the treatment of insomnia in China. It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABAA receptor with two- to four-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits.

Arketamine (developmental code names PCN-101, HR-071603), also known as '(R)-ketamine or (R)-(−)-ketamine', is the (R)-(−) enantiomer of ketamine. Similarly to racemic ketamine and esketamine, the S(+) enantiomer of ketamine, arketamine is biologically active; however, it is less potent as an NMDA receptor antagonist and anesthetic and thus has never been approved or marketed for clinical use as an enantiopure drug. Arketamine is currently in clinical development as a novel antidepressant.

Norketamine, or '''N-desmethylketamine''', is the major active metabolite of ketamine, which is formed mainly by CYP3A4. Similarly to ketamine, norketamine acts as a noncompetitive NMDA receptor antagonist, but is about 3–5 times less potent as an anesthetic in comparison.

α-Methylhistamine is a synthetic derivative and a selective histamine H3 receptor agonist. It decreases blood pressure and heart rate in guinea pigs. The drug also has sedative and hypnotic effects in animals.

Loreclezole is a sedative and an anticonvulsant which acts as a GABAA receptor positive allosteric modulator. The binding site of loreclezole has been shown experimentally to be shared by valerenic acid, an extract of the root of the valerian plant. Structurally, loreclezole is a triazole derivative. In animal seizure models, loreclezole is protective against pentylenetetrazol seizures but is less active in the maximal electroshock test. In addition, at low, nontoxic doses, the drug has anti-absence activity in a genetic model of generalized absence epilepsy. Consequently, loreclezole has a pr

Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc. Other cyclopyrrolone drugs include zopiclone, pagoclone and suriclone.

chemical compound